Group 1 - Eli Lilly and Company reported Q4 total revenues of $13.53 billion, reflecting a 45% year-on-year growth [2] - The net income for Q4 was $4.8 billion, with adjusted earnings per share (EPS) at $5.32, or $4.88 on a non-adjusted basis [2] - The company provides detailed financial models and research for investors, including product sales forecasts and market analysis [2]

Financial Performance - In 2024, Eli Lilly's full-year revenue grew by 32% compared to 2023, exceeding initial guidance by $4 billion [8] - Q4 revenue increased by 45%, driven by strong uptake of newly launched products [9][19] - Gross margin as a percentage of revenue rose to 83.2% in Q4, influenced by a favorable product mix [20] - Operating income more than doubled to $5.6 billion, with earnings per share reaching $5.32, compared to $2.49 in Q4 2023 [22] Business Line Performance - New products generated over $5.6 billion in Q4, with Mounjaro and Zepbound leading the growth [27] - The non-incretin portfolio grew by 20% in Q4, excluding one-time business development payments [20][13] - Trulicity revenue declined by 25%, primarily due to switches to Mounjaro [31] Market Performance - U.S. revenue increased by 40% in Q4, with volume growth of 45% [23] - European revenue grew by 82% in constant currency, benefiting from a one-time payment related to Jardiance [24] - Japan revenue rose by 27% in constant currency, driven by Mounjaro and other products [24] - Revenue in China increased by 13% in constant currency, with Mounjaro recently launched [26] Company Strategy and Industry Competition - Eli Lilly is focusing on expanding its pipeline through acquisitions and collaborations, including a partnership with OpenAI [10] - The company is investing over $23 billion in manufacturing facilities since 2020 to meet increasing demand [11] - The strategic focus includes launching Mounjaro in new markets and expanding access to existing products [34] Management Commentary on Operating Environment and Future Outlook - Management expressed confidence in the growth trajectory for 2025, anticipating revenue between $58 billion and $61 billion [33] - The company expects continued growth in oncology, neuroscience, and immunology sectors [35] - Management acknowledged potential headwinds from foreign exchange and pricing pressures but remains optimistic about long-term growth [35] Other Important Information - Eli Lilly returned $3 billion to shareholders through dividends and share repurchases, alongside a new $15 billion share repurchase program [17] - The company plans to initiate new Phase III programs in 2025, including trials for Orforglipron in hypertension [48] Q&A Session Summary Question: 2025 guidance and prescription uptake trends - Management confirmed that the 2025 guidance is based on the continuation of total prescription growth seen in 2024 [66][68] Question: Zepbound payer dynamics and access - Management indicated strong commercial access and anticipated Medicare coverage for OSA by the second half of the year [75] Question: Orforglipron positioning and efficacy - Management clarified that Orforglipron is expected to provide important benefits similar to existing GLP-1 therapies, particularly for patients with needle fear [86] Question: Sustainability of operating margin expansions - Management emphasized the importance of reinvesting in R&D to drive sustainable growth, indicating that high operating margins may not be realistic long-term [106] Question: Kisunla launch and market readiness - Management reported positive momentum in the Kisunla launch, focusing on system readiness and partnerships with healthcare providers [112] Question: Concerns about the obesity market size - Management reassured that the obesity market presents a significant opportunity, emphasizing ongoing demand and the need for further capacity building [126][128]

Core Insights - Eli Lilly and Company reported fourth-quarter 2024 adjusted earnings per share (EPS) of $5.32, exceeding the Zacks Consensus Estimate of $5.03, with a year-over-year increase of 114% [1] - Revenues for the quarter reached $13.53 billion, a 45% increase year-over-year, aligning with preliminary figures and surpassing the Zacks Consensus Estimate of $13.47 billion [1][2] Financial Performance - Adjusted earnings included a charge of 19 cents per share related to acquired in-process research and development [1] - Revenues benefited from a one-time payment of $300 million from Boehringer Ingelheim due to a collaboration amendment for Jardiance [2] - Sales of key growth products rose 13% to $5.95 billion, while new products contributed $5.64 billion to revenues [3] Product Sales Analysis - Mounjaro sales reached $3.53 billion, a 60% increase year-over-year, but missed the Zacks Consensus Estimate of $3.88 billion [5] - Zepbound recorded sales of $1.91 billion, up from $1.26 billion in the previous quarter, but also fell short of estimates [6] - Trulicity generated revenues of $1.25 billion, down 25% year-over-year, primarily due to competitive dynamics [10] - Jardiance sales rose 50% to $1.2 billion, benefiting from the one-time payment, despite a 1% decline in U.S. revenues [11] - Taltz and Verzenio saw sales increases of 21% and 36% year-over-year, respectively, both exceeding estimates [12][13] Geographic Revenue Breakdown - U.S. revenues increased by 40% to $9.03 billion, while ex-U.S. revenues rose 55% to $4.50 billion [4] Full-Year Performance - For the full year 2024, sales rose 32% to $45.04 billion, slightly missing the Zacks Consensus Estimate of $45.22 billion [16] - Adjusted earnings for 2024 were $12.99 per share, up 105.5% year-over-year, beating the Zacks Consensus Estimate [17] Future Outlook - For 2025, Lilly expects revenues between $58.0 billion and $61.0 billion, indicating a year-over-year growth of 32% [18] - EPS for 2025 is projected to be in the range of $22.50 to $24.00, with the Zacks Consensus Estimate at $23.79 [18] - The company anticipates increased production of incretin medicines and the launch of new drugs to drive sales growth in 2025 [22][23]

Core Insights - Eli Lilly's Q4 earnings report showed strong performance, with earnings per share at $5.32 and sales at $13.5 billion, surpassing analyst expectations of $5.08 per share and $13.4 billion in sales [1][2] Financial Performance - Q4 sales increased by 45% year over year, driven by strong demand for GLP-1 drugs Mounjaro and Zepbound, while non-GLP-1 drug sales also grew by 20% [2] - GAAP earnings per share more than doubled to $4.88, reflecting a 102% year-over-year growth, while full-year sales grew by 32% to $45 billion [3] Future Outlook - CEO David Ricks described 2024 as "highly successful," with projections for 2025 sales between $58 billion and $61 billion, indicating potential growth of up to 35.5% [4] - Earnings per share for 2025 are expected to range from $22.05 to $23.55, suggesting a strong outlook for continued earnings growth [4][5] - Current stock pricing at approximately 37 times the current year earnings, combined with the potential for doubling earnings annually, supports the argument for Eli Lilly stock as a buy [5]

Company Overview - Proactive is a financial news publisher that provides fast, accessible, informative, and actionable business and finance news content to a global investment audience [2] - The company operates with a team of experienced and qualified news journalists, ensuring independent content production [2] Market Focus - Proactive specializes in medium and small-cap markets while also covering blue-chip companies, commodities, and broader investment stories [3] - The news team delivers insights across various sectors, including biotech and pharma, mining and natural resources, battery metals, oil and gas, crypto, and emerging digital and EV technologies [3] Technology Adoption - Proactive is recognized for its forward-looking approach and enthusiastic adoption of technology to enhance workflows [4] - The company utilizes automation and software tools, including generative AI, while ensuring that all content is edited and authored by humans [5]

Core Viewpoint - Eli Lilly reported quarterly earnings of $5.32 per share, exceeding the Zacks Consensus Estimate of $5.03 per share, and showing significant growth from $2.49 per share a year ago, indicating a strong performance in the pharmaceutical sector [1][2]. Financial Performance - The company achieved revenues of $13.53 billion for the quarter ended December 2024, surpassing the Zacks Consensus Estimate by 0.44%, and up from $9.35 billion year-over-year [2]. - Over the last four quarters, Eli Lilly has surpassed consensus EPS estimates three times and topped revenue estimates two times [2]. Stock Performance - Eli Lilly shares have increased approximately 9.1% since the beginning of the year, outperforming the S&P 500's gain of 3.1% [3]. - The stock currently holds a Zacks Rank 3 (Hold), indicating expected performance in line with the market in the near future [6]. Earnings Outlook - The current consensus EPS estimate for the upcoming quarter is $4.72 on revenues of $12.7 billion, and for the current fiscal year, it is $23.79 on revenues of $59.63 billion [7]. - The trend of estimate revisions for Eli Lilly is mixed, which could change following the recent earnings report [6]. Industry Context - The Large Cap Pharmaceuticals industry is currently ranked in the bottom 31% of over 250 Zacks industries, suggesting potential challenges ahead [8].

Core Insights - Eli Lilly is set to release data from a late-stage trial of its weight loss drug retatrutide earlier than expected, later this year [1] - The company anticipates results from a study involving obesity and knee osteoarthritis patients in 2025, which was previously scheduled to conclude in February 2026 [2] - Retatrutide is a significant component of Eli Lilly's drug pipeline, potentially solidifying its leadership in the weight loss and diabetes treatment market against competitors like Novo Nordisk [3] Drug Mechanism and Efficacy - Retatrutide, known as the "triple G" drug, mimics three hunger-regulating hormones: GLP-1, GIP, and glucagon, leading to more effective appetite control and food satisfaction [3] - In a mid-stage trial, retatrutide resulted in an average weight loss of 24.2% (approximately 58 pounds) over 48 weeks, compared to a 2.1% loss in the placebo group [5] - Higher doses of Eli Lilly's tirzepatide have shown an average weight loss of up to 22.5% in late-stage studies, indicating strong competition in the weight loss drug market [4][5]

Group 1 - Eli Lilly reported net income of $4.41 billion, or $4.88 per share, on revenue of $13.53 billion, which was slightly below analyst expectations of $4.52 billion in profit and $13.56 billion in revenue [1] - Adjusted earnings per share (EPS) of $5.32 exceeded expectations of $5.11, indicating strong performance despite overall results being worse than expected [1] - Sales of weight-loss drugs Mounjaro and Zepbound reached $3.53 billion and $1.91 billion, respectively, falling short of expectations of $3.65 billion and $2.04 billion [2] Group 2 - Eli Lilly expects 2025 revenue to be between $58.0 billion and $61.0 billion, with EPS projected from $22.05 to $23.55, and adjusted EPS from $22.50 to $24.00, which aligns with or exceeds market expectations [2] - Following the earnings report, Eli Lilly shares rose more than 2%, reflecting positive market sentiment, while the stock has increased approximately 20% over the past year [3] - In contrast, rival Novo Nordisk's shares have declined about 25% in the past year, highlighting a competitive landscape in the weight-loss drug market [3]

Earnings and Revenue Guidance - Eli Lilly and Company will provide an update on 2024 earnings guidance and share its 2025 revenue guidance range during the 2025 J.P. Morgan Healthcare Conference[5] Market Trends Discussion - The company will discuss overall market trends during the conference[5] Conference Webcast and Materials - A live audio webcast of the conference discussion, press release, and associated presentation will be available on Lilly's Investor website[5] - The presentation replay will be available on the website for approximately 30 days[5] Regulatory and Filing Information - The information in Item 2.02, including Exhibit 99.1, is being furnished and shall not be deemed "filed" for the purposes of Section 18 of the Securities Exchange Act of 1934[6] - Exhibit 99.1 is a press release of Eli Lilly and Company dated January 14, 2025[7] Executive Signatory - The report is signed by Lucas Montarce, Executive Vice President and Chief Financial Officer of Eli Lilly and Company[10]

Core Insights - Eli Lilly reported mixed results for the fourth quarter, with strong sales from its weight loss drug Zepbound and diabetes drug Mounjaro, but lower realized prices impacting overall performance [1][2] - The company has lowered its 2024 revenue guidance due to expectations not being met for demand in its key drug segments [2] - Despite the challenges, Eli Lilly's quarterly earnings exceeded Wall Street estimates, although sales fell slightly short [2][6] Financial Performance - For the fourth quarter, Eli Lilly posted revenue of $13.53 billion, representing a 45% increase year-over-year [3] - The net income for the fourth quarter was $4.41 billion, or $4.88 per share, compared to $2.19 billion, or $2.42 per share, from the previous year [4] - Adjusted earnings per share were reported at $5.32, surpassing the expected $4.95, while revenue fell just short of the expected $13.57 billion [6] Future Guidance - Eli Lilly provided fiscal 2025 profit guidance of $22.05 to $23.55 per share, aligning with analyst expectations [3] - The company reiterated its fiscal 2025 sales guidance, projecting between $58 billion and $61 billion [3]